Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...

Nektar Therapeutics NKTR incurred a loss per share of 18 cents in the third quarter of 2024, narrower than the Zacks ...

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

Nektar Therapeutics (NASDAQ:NKTR) is scheduled to announce Q3 earnings results on Thursday, November 7th, after market close.

Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:NKTR), citing the company’s lead asset ...

Nektar Therapeutics ( NASDAQ:NKTR ) investors will be delighted, with the company turning in some strong numbers ...

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

Nektar Therapeutics ( (NKTR) ) has released its Q3 earnings. Here is a breakdown of the information Nektar Therapeutics presented to its ...

SAN FRANCISCO — SAN FRANCISCO — Nektar Therapeutics (NKTR) on Thursday reported a loss of $37.1 million in its third quarter. On a per-share basis, the San Francisco-based company said it had a loss ...

(RTTNews) - Nektar Therapeutics (NKTR), Monday announced a decision to sell its Alabama-based commercial-scale manufacturing facility and PEGylation reagent supply business to Ampersand Capital ...

Nektar Therapeutics ( (NKTR)) has released its Q3 earnings. Here is a breakdown of the information Nektar Therapeutics presented to its investors. Nektar Therapeutics is a clinical-stage ...